Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,630 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Radioligand therapies in cancer: mapping the educational landscape in Europe.
Bugani V, Battistelli L, Sansovini M, Monti M, Paganelli G, Gich I, Flotats A, Erba PA, Blay JY, la Fougère C, Van Poppel H, Charalambous A, Herrmann K, Giordano A, Györke T, Deroose C, Matteucci F, Carrió I. Bugani V, et al. Among authors: monti m. Eur J Nucl Med Mol Imaging. 2023 Jul;50(9):2692-2698. doi: 10.1007/s00259-023-06217-0. Epub 2023 Apr 14. Eur J Nucl Med Mol Imaging. 2023. PMID: 37058168 Free PMC article.
Endobronchial/Endoesophageal Ultrasound (EBUS/EUS) Guided Fine Needle Aspiration (FNA) and 18F-FDG PET/CT Scanning in Restaging of Locally Advanced Non-small Cell Lung Cancer (NSCLC) Treated with Chemo-radiotherapy: A Mono-institutional Pilot Experience.
Genestreti G, Burgio MA, Matteucci F, Piciucchi S, Scarpi E, Monti M, Bucchi L, Parisi E, Crociani L, Gurioli C, Poletti V, Gavelli G. Genestreti G, et al. Among authors: monti m. Technol Cancer Res Treat. 2015 Dec;14(6):721-7. doi: 10.7785/tcrt.2012.500437. Epub 2014 Nov 26. Technol Cancer Res Treat. 2015. PMID: 24945370 Free article.
Peptide receptor radionuclide therapy with (177)Lu-DOTATATE in advanced bronchial carcinoids: prognostic role of thyroid transcription factor 1 and (18)F-FDG PET.
Ianniello A, Sansovini M, Severi S, Nicolini S, Grana CM, Massri K, Bongiovanni A, Antonuzzo L, Di Iorio V, Sarnelli A, Caroli P, Monti M, Scarpi E, Paganelli G. Ianniello A, et al. Among authors: monti m. Eur J Nucl Med Mol Imaging. 2016 Jun;43(6):1040-6. doi: 10.1007/s00259-015-3262-8. Epub 2015 Nov 27. Eur J Nucl Med Mol Imaging. 2016. PMID: 26611427 Clinical Trial.
Long-term follow-up and role of FDG PET in advanced pancreatic neuroendocrine patients treated with 177Lu-D OTATATE.
Sansovini M, Severi S, Ianniello A, Nicolini S, Fantini L, Mezzenga E, Ferroni F, Scarpi E, Monti M, Bongiovanni A, Cingarlini S, Grana CM, Bodei L, Paganelli G. Sansovini M, et al. Among authors: monti m. Eur J Nucl Med Mol Imaging. 2017 Mar;44(3):490-499. doi: 10.1007/s00259-016-3533-z. Epub 2016 Oct 4. Eur J Nucl Med Mol Imaging. 2017. PMID: 27704193
Erratum to: Long-term follow-up and role of FDG PET in advanced pancreatic neuroendocrine patients treated with 177Lu-D OTATATE.
Sansovini M, Severi S, Ianniello A, Nicolini S, Fantini L, Mezzenga E, Ferroni F, Scarpi E, Monti M, Bongiovanni A, Cingarlini S, Grana CM, Bodei L, Paganelli G. Sansovini M, et al. Among authors: monti m. Eur J Nucl Med Mol Imaging. 2017 Feb;44(2):352. doi: 10.1007/s00259-016-3558-3. Eur J Nucl Med Mol Imaging. 2017. PMID: 27807661 No abstract available.
Dosimetry and safety of 177Lu PSMA-617 along with polyglutamate parotid gland protector: preliminary results in metastatic castration-resistant prostate cancer patients.
Paganelli G, Sarnelli A, Severi S, Sansovini M, Belli ML, Monti M, Foca F, Celli M, Nicolini S, Tardelli E, Marini I, Matteucci F, Giganti M, Di Iorio V, De Giorgi U. Paganelli G, et al. Among authors: monti m. Eur J Nucl Med Mol Imaging. 2020 Dec;47(13):3008-3017. doi: 10.1007/s00259-020-04856-1. Epub 2020 May 20. Eur J Nucl Med Mol Imaging. 2020. PMID: 32430583 Clinical Trial.
1,630 results